Deal Library / Pharma BD Deal Intelligence

Infectious Disease Deals

The Pharma Closeout tracks 68 deals, $265.2B in disclosed deal value, 47 with a post-close Outcome Score for Infectious Disease.

Median Critic Score: 75  ·  Median Outcome Score: 51

Best outcome: Pfizer Inc. / BioNTech SE (100)  ·  Weakest outcome: Bristol-Myers Squibb Company / Inhibitex Inc. (8)

All 68 deals

• Pfizer Inc. / BioNTech SE — 2020 · $748M · Worked — the deal delivered on its rationale.
• Gilead Sciences Inc. / Pharmasset Inc. — 2011 · $11.2B · Worked — the deal delivered on its rationale.
• Abbott Laboratories / Alere Inc. — 2016 · $5.8B · Worked — the deal delivered on its rationale.
• bioMerieux SA / BioFire Diagnostics Inc. — 2013 · $485M · Worked — the deal delivered on its rationale.
• Roche Holding AG / Ventana Medical Systems Inc. — 2008 · $3.4B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / MedImmune Inc. — 2007 · $15.6B · Worked — the deal delivered on its rationale.
• Roche Holding AG / IQuum, Inc. — 2014 · $450M · Worked — the deal delivered on its rationale.
• GSK plc / SmithKline Beecham — 2000 · $12.0B · Worked — the deal delivered on its rationale.
• Hologic Inc. / Gen-Probe Incorporated — 2012 · $3.8B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Crucell NV — 2003 · $2.4B · Worked — the deal delivered on its rationale.
• Chiron Corporation / PathoGenesis Corporation — 2000 · $700M · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Agouron Pharmaceuticals — 1999 · $2.1B · Largely worked — most objectives met.
• Sanofi SA / Translate Bio Inc. — 2018 · $805M · Largely worked — most objectives met.
• Sanofi SA / Protein Sciences Corp. — 2017 · $650M · Largely worked — most objectives met.
• Sanofi SA / Dynavax Technologies — 2025 · $2.2B · Largely worked — most objectives met.
• Glaxo Wellcome plc / SmithKline Beecham — 2000 · $76.0B · Largely worked — most objectives met.
• AstraZeneca PLC / Icosavax Inc. — 2023 · $1.1B · Largely worked — most objectives met.
• Glaxo plc / Wellcome plc — 1995 · $14.2B · Largely worked — most objectives met.
• Pfizer Inc. / BioNTech SE — 2018 · $425M · Mixed — partial payoff, real shortfalls.
• Xiamen Amoytop Biotech Co., Ltd. / Aligos Therapeutics, Inc. — 2026 · $445M · Mixed — partial payoff, real shortfalls.
• Pfizer Inc. / Novavax Inc. — 2026 · $530M · Mixed — partial payoff, real shortfalls.
• Novartis AG / Chiron Corporation — 2002 · $5.4B · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Novavax Inc. — 2024 · $1.2B · Mixed — partial payoff, real shortfalls.
• GlaxoSmithKline plc / Vir Biotechnology Inc. — 2020 · $595M · Mixed — partial payoff, real shortfalls.
• Johnson & Johnson (Janssen Pharmaceutica) / Vertex Pharmaceuticals (telaprevir ex-NA/ex-Far East rights) — 2006 · $545M · Mixed — partial payoff, real shortfalls.
• Novartis AG / Molecular Partners AG — 2020 · $780M · Mixed — partial payoff, real shortfalls.
• GenturaDx / LUMINEX CORP — 2012 · $50M · Mixed — partial payoff, real shortfalls.
• Warner-Lambert Company / Agouron Pharmaceuticals — 1999 · $2.1B · Mixed — partial payoff, real shortfalls.
• Horizon Pharma plc / Raptor Pharmaceutical Corp. — 2016 · $860M · Mixed — partial payoff, real shortfalls.
• Cubist Pharmaceuticals Inc. / Optimer Pharmaceuticals Inc. — 2013 · $801M · Mixed — partial payoff, real shortfalls.
• Cubist Pharmaceuticals Inc. / Trius Therapeutics Inc. — 2013 · $707M · Underwhelmed — fell short of the thesis.
• Merck & Co. Inc. / Cubist Pharmaceuticals — 2014 · $9.5B · Underwhelmed — fell short of the thesis.
• Pharmstandard OJSC / Bever Pharmaceutical Pte Ltd — 2013 · $590M · Underwhelmed — fell short of the thesis.
• Mylan N.V. / Novartis AG (TOBI franchise) — 2018 · $463M · Underwhelmed — fell short of the thesis.
• Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. — 2012 · $90M · Underwhelmed — fell short of the thesis.
• AstraZeneca plc / Pfizer Inc. — 2016 · $1.6B · Underwhelmed — fell short of the thesis.
• Novartis AG / Alcon Inc. — 2010 · $51.6B · Underwhelmed — fell short of the thesis.
• Novo A/S (Novo Holdings) / Xellia Pharmaceuticals — 2013 · $700M · Underwhelmed — fell short of the thesis.
• Hospira, Inc. / Orchid Chemicals & Pharmaceuticals (Generic Injectables Business) — 2010 · $400M · Did not work — the deal failed to deliver.
• Hospira Inc. / Orchid Chemicals & Pharmaceuticals Ltd. (API and R&D facilities) — 2012 · $200M · Did not work — the deal failed to deliver.
• Gilead Sciences, Inc. / Nimbus Apollo, Inc. (Nimbus Therapeutics subsidiary) — 2016 · $1.2B · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / ZymoGenetics, Inc. — 2010 · $885M · Did not work — the deal failed to deliver.
• Allergan plc / Tobira Therapeutics, Inc. — 2016 · $1.7B · Did not work — the deal failed to deliver.
• Roche Holding AG / Anadys Pharmaceuticals, Inc. — 2011 · $230M · Did not work — the deal failed to deliver.
• Roche Holding AG / Anadys Pharmaceuticals, Inc. — 2010 · $230M · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / Idenix Pharmaceuticals — 2014 · $3.9B · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Inhibitex Inc. — 2012 · $2.5B · Did not work — the deal failed to deliver.
• Sino Biopharmaceutical Limited / GSK plc — 2026
• Eli Lilly and Company / LimmaTech Biologics AG — 2026 · $780M
• Novo Nordisk A/S / Akero Therapeutics, Inc. — 2025 · $5.2B
• Mirum Pharmaceuticals, Inc. / Bluejay Therapeutics, Inc. — 2025 · $820M
• GSK plc / CureVac N.V. — 2024 · $1.6B
• GSK plc / SCYNEXIS, Inc. — 2023 · $593M
• Sanofi SA / Janssen Pharmaceuticals, Inc. (Johnson & Johnson) — 2023 · $175M
• Pfizer Inc. / Valneva SE (VLA15 collaboration update) — 2022 · $363M
• GSK plc / Spero Therapeutics, Inc. — 2022 · $600M
• Merck & Co. Inc. / Orna Therapeutics, Inc. — 2022 · $3.6B
• Roche Holding AG / Atea Pharmaceuticals, Inc. — 2020 · $1.4B
• Pfizer Inc. / Valneva SE — 2020 · $308M
• GlaxoSmithKline plc / CureVac N.V. — 2020 · $960M
• Sanofi SA / Translate Bio Inc. — 2020 · $2.3B
• Roche Holding AG / Regeneron Pharmaceuticals, Inc. — 2020
• Moderna, Inc. / Lonza Group AG — 2020
• Merck & Co. Inc. / Immune Design Corp. — 2019 · $300M
• Boehringer Ingelheim GmbH / Yuhan Corporation — 2019 · $870M
• Gilead Sciences, Inc. / Tibotec Pharmaceuticals (Janssen) — 2011
• Vertex Pharmaceuticals Incorporated / Alios BioPharma, Inc. — 2011 · $1.5B
• ICN Pharmaceuticals Inc. (corporate restructuring) / ICN three-way split (Ribapharm carve-out) — 2000

← Deal Library  ·  Interactive search  ·  How we score deals